The nomogram was built on data of 321 patients with Stage III–IV NSCLC, and NLR, SOX2, GBU4‐5, and MAGEA1 were identified as significantly associated factors that could be combined for accurate prediction of therapeutic effect after chemotherapy. This evidence concerns the gene SOX2 and non-small cell lung carcinoma.